Details for Patent: 11,484,535
✉ Email this page to a colleague
Which drugs does patent 11,484,535 protect, and when does it expire?
Patent 11,484,535 protects VITRAKVI and is included in one NDA.
This patent has fifty-seven patent family members in twenty-eight countries.
Drugs Protected by US Patent 11,484,535
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Healthcare | VITRAKVI | larotrectinib sulfate | SOLUTION;ORAL | 211710-001 | Nov 26, 2018 | RX | Yes | Yes | 11,484,535 | ⤷ Subscribe | METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,484,535
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 108090 | ⤷ Subscribe | |||
Australia | 2017246547 | ⤷ Subscribe | |||
Australia | 2017246554 | ⤷ Subscribe | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |